Omega-3/omega-6 fatty acids for attention deficit hyperactivity disorder: a randomized placebo-controlled trial in children and adolescents.

• Objective: The aim of the study was to assess omega 3/6 fatty acids (eye q) in attention deficit hyperactivity disorder (ADHD). Method: The study included a randomized, 3-month, omega 3/6 placebo-controlled, one-way crossover trial with 75 children and adolescents (8–18 years), followed by 3 months with omega 3/6 for all. Investigator-rated ADHD Rating Scale–IV and Clinical Global Impression (CGI) scale were outcome measures. Results: A majority did not respond to omega 3/6 treatment. However, a subgroup of 26% responded with more than 25% reduction of ADHD symptoms and a drop of CGI scores to the near-normal range. After 6 months, 47% of all showed such improvement. Responders tended to have ADHD inattentive subtype and comorbid neurodevelopmental disorders. Conclusion: A subgroup of children and adolescents with ADHD, characterized by inattention and associated neurodevelopmental disorders, treated with omega 3/6 fatty acids for 6 months responded with meaningful reduction of ADHD symptoms.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Psykiatri (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Psychiatry (hsv//eng)

Nyckelord

Adolescent

Attention Deficit Disorder with Hyperactivity

Diagnosis

Drug therapy

Autistic Disorder

Diagnosis

Drug therapy

Child

Comorbidity

Cross-Over Studies

Double-Blind Method

Dyslexia

Diagnosis

Drug therapy

Fatty Acids

Omega-3

Therapeutic use

Fatty Acids

Omega-6

Therapeutic use

Follow-Up Studies

Humans

Learning Disorders

Diagnosis

Drug therapy

Motor Skills Disorders

Diagnosis

Drug therapy

Personality Assessment

Writing

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)